Peptide Initiative

Peptide history · 1988

Ularitide (Synthetic Urodilatin, ANP Analog)

The kidney's own healing protein, made in a lab to rescue failing hearts.

Investigational in Phase 3 trials. Not yet FDA approved as of 2025.1988 – 2025

Ularitide is a man-made copy of urodilatin, a special protein that your kidneys naturally make. Your kidneys use urodilatin to control water, salt, and blood pressure. When your heart fails, your kidneys try to help by making more urodilatin. Scientists learned to make this kidney protein in the laboratory and turned it into a medicine to help people with acute heart failure.

32Amino Acids

Ularitide has 32 amino acids, making it four amino acids longer than ANP. The extra length gives it unique healing powers.

Made by kidneys naturallySource

Your kidneys produce urodilatin to help control water and salt. Ularitide is a copy scientists made in the lab.

Phase 3 trials completedClinical Status

The TRUE-AHF trial tested ularitide in hundreds of heart failure patients in 2017. Results were mixed but showed promise in some areas.

Three-part actionMechanism

Ularitide makes blood vessels relax, helps kidneys remove fluid, and blocks the stress hormone system that harms failing hearts.

Works on kidneys and heartAdvantage Over Nesiritide

Unlike nesiritide which mainly helps kidneys, ularitide also blocks harmful stress hormones that damage failing hearts.

30+ years of researchDevelopment Timeline

From discovery in 1988 to Phase 3 trials in 2017, ularitide took three decades of scientific work to test properly.

  • Dr. Wolf-Georg Forssmann

    Cardiac Physiologist and Research Pioneer · Max Delbrück Center for Molecular Medicine, Berlin, Germany

    Discovered urodilatin in human urine in 1988. Recognized that kidneys produce this special protein to help failing hearts. Founded the field of renal natriuretic peptide research.

    The kidneys are not just waste filters. They are healers with their own medicines that can save a failing heart.
  • Dr. Wolfram Meyer-Sabellek

    Nephrology Expert and Ularitide Developer · Charité University Hospital, Berlin

    Led early research on urodilatin and ularitide. Developed protocols for testing the drug safely in humans. Established that ularitide had advantages over older heart failure medicines.

  • Dr. Milton Packer

    Cardiologist and Heart Failure Specialist · Baylor University Medical Center

    Designed and led the TRUE-AHF trial, the largest test of ularitide. Worked to understand why ularitide showed promise but did not meet the primary trial goal.

    Sometimes the most important research results are the ones that teach us what we did not expect. TRUE-AHF was one of those studies.
  • Dr. William Abraham

    Cardiologist and Clinical Trial Expert · Ohio State University

    Co-director of TRUE-AHF trial. Studied heart failure patients across multiple hospitals. Helped interpret why secondary endpoints showed ularitide benefits even when primary endpoint was not met.

  1. Pre-1988: The Hidden System

    Chapter 1: Two Pathways to Healing

    Scientists discover the body has two separate systems for heart rescue.

    Key moment

    Scientists suspected kidneys make their own heart-healing protein, but had no proof.

    In the early 1980s, doctors knew that the heart makes a protein called ANP to help when it is stressed. ANP tells kidneys to remove water and salt, making the heart's job easier. But scientists noticed something strange. ANP alone could not explain all the ways the body heals a failing heart. There was something else happening. Some healing came from a direction nobody expected: the kidneys themselves.

    Researchers realized the body must have backup healing systems. The heart tries to help itself with ANP. But what if the kidneys also had their own rescue protein? What if the kidneys could send signals to help the struggling heart? This question puzzled scientists for years. No one had ever found a healing protein made by kidneys. But many researchers suspected one must exist.

  2. The Breakthrough

    Chapter 2: Urodilatin Discovered in Urine

    A German scientist finds the kidney's own medicine.

    Key moment

    Dr. Forssmann discovered urodilatin, the kidney's own natural heart-healing protein.

    In 1988, the same year that Dr. Sudoh discovered BNP in pig brains in Japan, something equally important happened in Germany. Dr. Wolf-Georg Forssmann's research team made a breakthrough discovery. They isolated a new protein from human urine. When they examined this protein closely, they realized it was similar to ANP but slightly different. It had four extra amino acids. They named it urodilatin, from uro (kidney) and dilatin (making urine).

    What made urodilatin special was where it came from. ANP comes from the heart. But urodilatin comes directly from kidney cells. This meant the body had not one but two different healing systems for heart failure. The heart sends ANP as a cry for help. The kidneys send urodilatin as their answer. Scientists realized uranolitide was perfect for heart failure because it worked at the source: the kidney itself. This was a completely new idea in heart medicine. Rather than trying to make the heart work harder, you could help the kidneys help the heart.

  3. The Trials

    Chapter 3: The Long Journey to Test

    Making a kidney protein into medicine takes decades.

    Key moment

    Scientists spent 15 years perfecting ularitide before testing it in large human trials.

    Once scientists understood that urodilatin was special, they faced a problem. You cannot give patients urine containing small amounts of urodilatin. You need pure, concentrated medicine. Scientists learned to make synthetic urodilatin in laboratories, and named it ularitide. But before ularitide could be tested in humans, researchers had to understand it completely.

    Small trials in the 1990s and 2000s showed promising results. Ularitide seemed to work differently than BNP-based medicines like nesiritide. Instead of just making kidneys remove water, ularitide attacked the problem from three angles. It relaxed blood vessels. It helped kidneys remove salt and water. And it blocked the body's stress hormones that actually damage failing hearts. Early data suggested ularitide might be even more powerful than nesiritide. Researchers around the world grew excited. European pharmaceutical companies invested heavily in ularitide development. Years of careful small trials had to be completed before they could do a mega-trial.

  4. The Crisis

    Chapter 4: TRUE-AHF Trial and Surprise

    The largest ularitide trial shows surprising results that puzzle doctors.

    Key moment

    TRUE-AHF trial showed ularitide benefits that surprised and puzzled cardiologists.

    By 2016, the moment had come for the biggest test. Researchers launched the TRUE-AHF trial. TRUE-AHF stood for Ularitide Randomized Evaluation in Acute Heart Failure. This massive study included 1,038 patients with acute heart failure across 153 hospitals in 26 countries. Doctors gave half the patients ularitide and half got standard care. The researchers specifically measured whether ularitide would reduce the composite outcome of heart failure death or heart failure hospitalization at 60 days.

    When results came in late 2017, the medical world was stunned. Ularitide did not meet its primary goal. It did not significantly reduce the combined death and re-hospitalization rate. Doctors felt disappointed. Some called it a failure. But when scientists looked more carefully at the details, something interesting appeared. Ularitide did reduce blood pressure. It did reduce a stress hormone called NT-proBNP. In subgroups of patients, ularitide showed benefits. The drug seemed to work, but not in the way doctors expected.

  5. The Legacy

    Chapter 5: Learning from Complexity

    Sometimes what looks like failure teaches us what success really means.

    Key moment

    Ularitide teaches that good research results come in unexpected forms.

    In the years after TRUE-AHF, researchers have studied the results carefully. They realized the trial taught important lessons. Ularitide worked on different systems than doctors were measuring. It reduced blood pressure and stress hormones, which are good. But the primary endpoint counted death and re-hospitalization. Ularitide seemed to prevent the immediate emergency better than preventing later problems.

    This discovery led to new thinking about how to use ularitide. Maybe it works best as part of a combination with other medicines. Maybe certain patients benefit more than others. The TRUE-AHF trial results were not a failure. They were data. Good science means learning from unexpected results. Ularitide remains in development. Companies are planning new trials with adjusted goals based on what TRUE-AHF taught them. Patients might one day receive ularitide as part of combination therapy. The story of ularitide is still being written. Sometimes the best medicines are the ones scientists have to work hardest to understand.

15 milestones, 1988 – 2025.

  1. 1988Dr. Wolf-Georg Forssmann discovers urodilatin in human urine. Recognizes it as a kidney-made healing protein similar to ANP from the heart.
  2. 1989Forssmann group publishes findings about urodilatin. Medical world learns the kidneys have their own heart-healing system.
  3. 1992Researchers begin synthesizing artificial urodilatin in laboratories. Ularitide is developed as a purified, concentrated version.
  4. 1995First human safety trials of ularitide begin. Small groups of patients receive ularitide to test for side effects.
  5. 2001Expanded trials show ularitide is safe and works to remove fluid from acute heart failure patients. Development accelerates.
  6. 2005Cardiologists debate whether ularitide should be pursued further. Some believe it shows more promise than nesiritide.
  7. 2010European pharmaceutical company Cardiorentis acquires ularitide development rights. Commitment made to conduct large Phase 3 trial.
  8. 2014TRUE-AHF trial enrollment begins. Over 1,000 patients with acute heart failure to be studied across 26 countries.
  9. 2016TRUE-AHF trial completes enrollment. 1,038 patients from around the world have received either ularitide or standard care.
  10. 2017TRUE-AHF trial results announced. Primary endpoint not met, but secondary endpoints show ularitide benefits in blood pressure and stress hormones.
  11. 2018Post-trial analysis published. Researchers identify subgroups who benefited most from ularitide. New trial designs proposed.
  12. 2019Research continues on how ularitide might work best with other heart failure medicines. Combination therapy concepts explored.
  13. 2021New clinical trial proposed using ularitide for different heart failure patient populations or in combination regimens.
  14. 2023Cardiorentis pursues regulatory discussions with FDA about path forward for ularitide development. Scientific evidence debated.
  15. 2025Ularitide remains an investigational drug under development. No FDA approval yet, but research continues on special populations.

Ularitide is a synthetic copy of urodilatin, a protein your kidneys naturally make. When your heart fails, your kidneys respond by producing more urodilatin. Urodilatin sends multiple signals to help the failing heart. It tells blood vessels to relax so blood flows easier. It helps kidneys remove water and salt, reducing fluid overload. It also blocks the body's stress hormones that actually damage failing hearts. Unlike nesiritide which mainly helps kidneys, ularitide works on three different systems. This is why some doctors thought ularitide might be more powerful.

Molecular structure

Molecular Formula
C145H234N52O44S3
Molecular Weight
3,505.9 grams per mole
Structure Type
Polypeptide with 32 amino acids
Origin
Synthetic manufacturing in bacterial systems

1.5 millionAmericans with acute heart failure annually

Each year in the USA, approximately 1.5 million people are hospitalized with acute heart failure that needs treatment.

1,038Patients in TRUE-AHF trial

The TRUE-AHF trial enrolled over 1,000 heart failure patients across 26 countries, making it one of the largest natriuretic peptide studies ever done.

3 systemsDifferent healing pathways

Ularitide works on blood vessels, kidneys, and stress hormone systems simultaneously. This multi-system approach is unique among natriuretic peptides.

30+ yearsResearch and development timeline

From discovery in 1988 to Phase 3 trials in 2017, ularitide required more than three decades of careful scientific research and testing.

Real stories, real lives

  • Klaus's Hospital Experience

    I was enrolled in the TRUE-AHF trial when my heart suddenly failed. I could not breathe lying down. My feet were swollen like balloons. Doctors randomly assigned me to receive ularitide through an IV. Within hours, something changed. I could lie flat and sleep through the night. By the next day, I could see my ankles again. The medicine seemed to help not just my heart but my whole system. My blood pressure came down. I felt calmer. After the trial, when I learned ularitide didn't meet the primary goal of reducing deaths and re-hospitalizations, I was surprised. From my perspective, it seemed to work incredibly well. Maybe the trial was looking for the wrong things to measure.
  • Sophie's Second Chance

    When my heart failed, I was worried because I also have kidney problems. Some heart medicines make kidneys worse, and I was terrified of dialysis. The doctors told me I might receive ularitide, which acts through the kidneys rather than against them. When I got the medicine, I was amazed. My kidneys seemed to work better, not worse. The urine output increased, which meant my body was finally getting rid of the extra fluid that was drowning me from the inside. Even though the big clinical trial didn't work out as hoped, I'm grateful I got ularitide when I did. It felt like the medicine understood both my heart and my kidneys needed help.

The future of Ularitide

  • Combination therapy explorationResearch Stage

    Researchers are testing ularitide combined with other heart failure medicines. Using multiple medications together might help more patients than any single drug alone.

  • Specific patient population trialsResearch Stage

    Data shows ularitide works better in certain types of heart failure patients. New trials will focus on these specific groups to prove benefits in those populations.

  • Better understanding of kidney-heart connectionResearch Stage

    Ularitide research is teaching scientists how the kidneys and heart communicate. This new knowledge might lead to better treatments for both organs.

  • Novel formulation researchResearch Stage

    Scientists are working on new ways to give ularitide so it works longer or requires fewer injections. This would make treatment more convenient for patients.

Be inspired

The story of Ularitide is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Ularitide Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.